# Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

> **NCT00313586** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 197 (actual)

## Conditions studied

- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Adult Acute Myeloid Leukemia in Remission
- Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1
- Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL
- Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA
- Alkylating Agent-Related Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- de Novo Myelodysplastic Syndrome
- Previously Treated Myelodysplastic Syndrome
- Recurrent Adult Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Secondary Myelodysplastic Syndrome
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Entinostat
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT00313586
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2017-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00313586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00313586, "Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00313586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*